Surface CEO plans to break through in immuno-oncology

5 September 2019

Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology (Nasdaq: SURF) have had a rough time since the company went public in New York, early in 2018.

After climbing to a peak value of $17 in early July 2018, the company’s share price has fallen steadily and surely, to its current all-time low of around $2 - a loss of nearly 90%.

Led by Jeff Goater, erstwhile investment banker and former chief financial officer at Voyager Therapeutics (Nasdaq: VYGR), Surface is focused on the tumor microenvironment, and has a pipeline of seven novel immunotherapies plus a strategic collaboration with Swiss giant Novartis (NOVN: VX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK